Latest Animal Health Sector News

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.

Apiam Animal Health has secured court approval for its corporate scheme, paving the way for a fully franked special dividend payment next month.

Apiam Animal Health Limited has announced a special fully franked dividend of AUD 0.10 per share, with payment scheduled for mid-February 2026. Notably, the company has suspended its dividend reinvestment plan for this payout.

Apiam Animal Health posted modest FY25 revenue growth but saw net profit plunge due to asset impairments, while receiving a non-binding acquisition proposal from Adamantem Capital.

Apiam Animal Health posted modest FY25 growth amid challenges in clinical services, launching a Strategic Reset Program and attracting an acquisition proposal from Adamantem Capital.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 45 active trials worldwide and anticipates UK revenue by Q2 FY26 following successful supermarket partnerships.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.